42 results about "Arteriosclerosis obliterans" patented technology

It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) 12 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) 12 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and / or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.

The invention discloses a compound cell preparation, a preparation method and application of the preparation. The preparation comprises autologous platelet rich plasma (PRP), autologous adipose derived stromal cells (ADSCs) and endothelial progenitor cells (EPCs) of ADSC sources. The preparation method comprises the following steps that fat is collected, and adipocyte is separated; the adipocyte is cultured through an ADSC culture medium to obtain P2-generation autologous ADSCs; the P2-generation autologous ADSCs are cultured through an EPC culture medium to obtain EPCs of P0-generation ADSC sources; anticoagulation peripheral blood of a receptor is collected and centrifuged to obtain PRP, and the application of the compound cell preparation in the medicine for treating lower extremity arteriosclerosis obliterans due to diabetes is achieved. The compound cell preparation has the advantages that the EPC culture medium is adopted for inducing the ADSCs to be cultured, the EPCs with the expression percentage of CD133 as 68.72+ / -11.60% and the expression percentage of vWF as 75.91+ / -9.83% are obtained, bone marrow or mobilized peripheral blood does not need to be collected, and after affected parts of patients with lower extremity arteriosclerosis obliterans due to diabetes are injected with the preparation, the limb pain feeling and cold feeling can be lowered, and the new generation rate of collateral vessels is 100%; the total survival rate is 78.12%, the limb salvage survival rate is 68.00%, and the survival life of artificial limbs of the patients can be effectively prolonged.

The objective of the invention is to provide an agent for prevention and treatment of acute renal failure which is caused by the following lasting or aggravated diseases: systemic inflammatory response syndrome caused by trauma, burn, pancreatitis, septicemia or infection; DIC syndrome; multiple organ failure; peripheral arterial occlusive disease; occlusive atherosclerosis; and crush syndrome; or post-transplantation complication. The invention is an agent for prevention and treatment of acute renal failure, which contains a hydantoin derivative represented by the general formula below as an active ingredient. Among such compounds, (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide is particularly preferable. (Formula) (In the formula, X represents a halogen atom or a hydrogen atom, and R<1> and R<2> independently represent a hydrogen atom or an optionally substituted C1-6 alkyl group, or R<1> and R<2> are combined with nitrogen atom to which R<1> and R<2> are connected or optionally another nitrogen atom or oxygen atom to form 5- and 6-membered heterocycle.